In July, Angioline, a Novosibirsk-based company which holds about 20% of the coronary stents market in Russia, will launch the construction of a new production facility for manufacturing heart valves. This was announced by Andrei Kudryashov, the Director of the company.
“In the next two to three years, we plan to enter the market of heart valves and other products for cardiac surgery. We will start the construction of a new production facility at the Biotechnopark in early July. The facility will be built by 2019, and then we will be launching new products, including aortic valves. This is what really makes it possible to reduce mortality,” said Mr. Kudryashov without specifying the expected volumes of production.
According to him, today, 96% of devices used in Russia for cardiac surgery are of foreign origin.
“For the stents, we managed to reverse this situation. We hold 18-20% of the Russian market and, in two to three years, we plan to capture up to half of it,” he said.
The company competes with US and Chinese manufacturers of stents. The new production facility of Angioline will cost 500 million rubles. The company is implementing the project entirely at its own expense.